Robert S. Lee, MD

Cardiology, Nuclear Cardiology, Echocardiography and Interventional Cardiology

• Certified in Interventional Cardiology
  American Board of Internal Medicine
  2013 (Expires 2023)
• Certified in Cardiovascular Disease
  American Board of Internal Medicine
  2012 (Expires 2022)
• Diplomate, Echocardiography
  National Board of Echocardiography
  2011 (Expires 2021)
• Diplomate, Nuclear Cardiology
  Certification Board of Nuclear Cardiology
  2010 (Expires 2020)
• Certified in Internal Medicine
  American Board of Internal Medicine
  2008 (Expires 2018)
• Drug Enforcement Administration (DEA) Certificate
  2006
• California State Licensure
  Medical Board of California
  2006 (Expires 2020)

• English
• Spanish
• Korean

Harbor-UCLA Medical Center

• Ad Hoc Committee for the Internal Review of the Pediatric Neonatal/Perinatal Training Program
  April 2009
• Clinical Radiology Committee
  2008 – 2009
• Utilization Review Committee
  2008 – 2009
• Internal Medicine Quality Improvement Committee
  2008 – 2009
• Intern Selection Committee
  2008 – 2009

• American Society for Cardiovascular Angiography and Interventions (FSCAI)
  Member
• American College of Cardiology (FACC)
  Member
• American Heart Association (AHA)
  Member

Articles

• Ahmadi N, Hajsadeghi F, Gul K, Leibfried M, DeMoss D, Lee R, Flores F, Nasir K, Hecht H, Naghavi M, Budoff MJ. Vascular Function Measured by Fingertip Thermal Reactivity is Impaired in Patients with Metabolic Syndrome and Diabetes Mellitus. Journal of Clinical Hypertension, November 2009; 11(11): 678-84.
• Ibebuoju UN, Nasir K, Gopal A, Ahmadi N, Mao SS, Young E, Honoris L, Nuguri VK, Lee RS, Usman N, Rostami B, Pal R, Flores F, Budoff MJ. Comparison of Atherosclerotic Plaque Burden and Composition Between Diabetic and Non-diabetic Patients by Non-invasive CT Angiography. International Journal of Cardiovascular Imaging, October 2009; 25(7): 717-23.
• Nagarakanti R, Sodhi S, Lee R, Ezekowitz M. Chronic Antithrombotic Therapy in Post- Myocardial Infarction Patients. Cardiology Clinics, May 2008; 26(2): 277-88.
• Sodhi S, Lee R, Ezekowitz M. Chronic Antithrombotic Therapy in Post-Myocardial Infarction Patients. Clinics in Geriatric Medicine, February 2006; 22(1): 167-82.

Abstracts

• RS Lee, R Kaushal, T Bholat, KA Zhiroff, SC Jaquez, QT Bui, JL Thomas, WJ French. Patient Differences by Mode of Hospital Arrival for ST-Elevation Myocardial Infarction Treated with Primary PCI. Journal of the American College of Cardiology, November 2011; 58(20): B91.
• Jug B, Papazian J, Lee R, Budoff MJ. Association of Lipoprotein Subfractions and Coronary Calcifications in Individuals at Intermediate Cardiovascular Risk. Journal of Cardiovascular Computed Tomography, June 2011; 5(4): S16.
• Hajsadeghi F, Ahmadi N, Lee R, Sarlak B, Ramirez J, Flores F, Mao SS, Budoff MJ. Low Density Lipoprotein, High Density Lipoprotein and Lipoprotein (a) Subclasses and Their Relationship With Coronary Artery Calcification Is Asymptomatic Population. Journal of the American College of Cardiology, March 2008; 51(10): A150.
• Ibebuogu UN, Nasir K, Gopal A, Ahmadi N, Mao SS, Young E, Honoris L, Nuguri VK, Lee R, Usman N, Rostami B, Pal R, Flores F, Budoff M. Comparison of Coronary Atherosclerotic Plaque Burden and Composition Between Diabetic and Nondiabetic Patients by Noninvasive CT Angiography. Arteriosclerosis, Thrombosis, and Vascular Biology, June 2008; 28(6): e134-e135.
• Lee R, Hajsadeghi F, Ramirez R, Sarlak B, Gopal A, Ahmadi N, Budoff MJ. Insulin Resistance and Coronary Artery Calcification measured by Electron Beam Computed Tomography. Circulation, October 2007; 116(16): S611.
• Budoff MJ, Lee R, Hajsadeghi F, Ahmadi N, Gopal A, Flores F. Homocysteine, Lipid Parameters, and Inflammatory Markers Relationship to Advanced Coronary Atherosclerosis on CT. Journal of Cardiovascular Computed Tomography, July 2007; 1(15): S9.
• Budoff MJ, Gao YL, Child J, Carson S, Liu SL, Young E, Lee RS, Zemsky A, Shareghi S, Gopal A, Mao SS. A Comparison of Electron Beam Computed Tomography and 64-Channel Multislice Computed Tomography Scanner in Measuring Coronary Artery Calcium. Journal of Nuclear Cardiology, April 2007; 14(2): S92.
• Seto TC, Barrett M, Bradley J, Lee R. Mastering Cardiac Auscultation over the Internet: Use of Computer-based Testing to Demonstrate the Power of Repetition. Chest, October 2004; 126(4): 880-881Sb.
• Lee RS, Devereaux DC, Hamilton MA, Kobashigawa JA. Is Corticosteroid Weaning More Successful in Older Heart Transplant Patients? Journal of Investigative Medicine, January 2000; 48(1): 3A.
• Kobashigawa JA, Takemoto S, Wener L, Tobis J, Lee R, Kumar N, Chuang JM, Moriguchi JD, Kawata N, Laks H. Development of Circulating, IgG Class I Antibodies is Associated with Increase in Intimal Thickness by Intravascular Ultrasound (IVUS) after Heart Transplant. The Journal of Heart and Lung Transplantation, January 2000; 19(1): 81-82.
• Kobashigawa J, Kubak B, Camara R, Inglish J, Lee R, Moriguchi J, Hamilton M, Hage A, Kawata N, Laks H. Effective Cytomegalovirus Prophylaxis with Intravenous Followed by Oral Ganciclovir for Donor Positive/Recipient Negative Mismatch. Transplantation, April 15, 1999; 67(7): S102.
• Lee RS, Ro TK, Hamilton MA, Kobashigawa JA. Treatment of Hypertension in Cardiac Transplant Recipients with Irbesartan. Journal of Investigative Medicine, February 1999; 47(2): 5A.
• Kobashigawa JA, Ro TK, Moriguchi JD, Lee RS, Cassem JD, Hamilton MA, Hage A, Kawata N, Laks H. Hemodynamic Compromising Rejection is Associated with Increased Incidence of Transplant Coronary Artery Disease in Cardiac Transplant Recipients. The Journal of Heart and Lung Transplantation, January 1999; 18(1): 50.
• Inglish JA, Hamilton MA, Lee RS, Kobashigawa JA. Effective Cytomegalovirus Prophylaxis with Intravenous Followed by Oral Ganciclovir. Journal of Investigative Medicine, March 1998; 46(3); 200A.

Presentations

• RS Lee, R Kaushal, T Bholat, KA Zhiroff, SC Jaquez, QT Bui, JL Thomas, WJ French. Patient Differences by Mode of Hospital Arrival for ST-Elevation Myocardial Infarction Treated with Primary PCI. Transcatheter Cardiovascular Therapeutics, San Francisco, CA, November 8, 2011.
• Wallin D, Hunt D, Lee R. Adrenal Insufficiency: An Unusual Cause of Hypercalcemia. Solomon Scholars, University of California at Los Angeles, Los Angeles, CA, June 9, 2009.
• Yan E, Lee, R, Swerdloff R. A Case of Elephantiasic Nodular Pretibial Myxedema? Solomon Scholars, University of California at Los Angeles, Los Angeles, CA, June 9, 2009.
• Lee R, Hajsadeghi F, Ahmadi N, Gopal A, Flores F, Budoff M. Serum Inflammatory Markers and Coronary Artery Calcification. Solomon Scholars, University of California at Los Angeles, Los Angeles, CA, June 12, 2007.
• Lee RS, Devereaux DC, Hamilton MA, Kobashigawa JA. Is Corticosteroid Weaning More Successful in Older Heart Transplant Patients? American Federation for Medical Research, Western Regional Meetings, Carmel, CA, February 9-12, 2000.
• Lee RS, Ro TK, Hamilton MA, Kobashigawa JA. Treatment of Hypertension in Cardiac Transplant Recipients with Irbesartan. American Federation for Medical Research, Western Regional Meetings, Carmel, CA, January 27-30, 1999.

• Interventional Cardiology  Fellowship
  Harbor-UCLA Medical Center/Good Samaritan Hospital
  Torrance, CA/Los Angeles, CA
  2012 – 2013
• Chief Fellow, General Cardiology
  Harbor-UCLA Medical Center
  Torrance, CA
  2011 – 2012
• Chief Resident, Internal Medicine
  Harbor-UCLA Medical Center
  Torrance, CA
  2008 – 2009
• Residency, Internal Medicine
  Harbor-UCLA Medical Center
  Torrance, CA
  2006 – 2008
• Internship, Internal Medicine
  Harbor-UCLA Medical Center
  Torrance, CA
  2005 – 2006
• Medical Doctorate (MD)
  Drexel University, College of Medicine, Class of 2005
  Philadelphia, PA
  2001 – 2005
• Certificate, Interdepartmental Medical Sciences Program
  Medical College of Pennsylvania, Hahnemann University
  Philadelphia, PA
  2000 – 2001
• Bachelor of Science, Biochemistry
  Minor, Applied Developmental Psychology
  University of California Los Angeles, Class of 2000
  Los Angeles, CA
  1995 – 2000

• AEGIS: A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects with Acute Coronary Syndrome.
  Sub-Investigator | 2019
  Sponsor: CSL Behring LLC
  NCT03473223
• COVET: Comparison of Oral anticoagulants for extended Venous Thromboembolism (COVET). It is a randomized, open label, active comparator to determine whether the direct oral anticoagulant apixaban and rivaroxaban are safer than warfarin (fewer bleeding complications) and still as effective as warfarin (no increase in recurrent blood clots).
  Sub-Investigator | 2018 – Present
  Sponsor : Patient-Centered Outcomes Research Institute (PCORI)
  NCT03196349
• NODE 301: Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Efficacy, and Safety Study of Etripamil Nasal Spray for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia.
  Sub-Investigator | 2019
  Sponsor: Milestone Pharmaceuticals Inc.
  NCT03464019
• NODE 302: Multi-Centre, Open-Label, Safety Study of Etripamil Nasal Spray in Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia (Extension of NODE-301).
  Sub-Investigator | 2019
  Sponsor: Milestone Pharmaceuticals Inc.
  NCT03635996
• PARADISE MI: A multi-center, randomized, double-blind, active-controlled, parallel-group Phase 3 study to evaluate the efficacy and safety of LCZ696 compared to ramipril on morbidity and mortality in high risk patients following an acute myocardial infarction.
  Sub-Investigator | 2018 – Present
  Sponsor: Novartis
  NCT02924727
• PEA-VALVE: Phono- and Electrocardiogram Assisted Detection of Valvular Disease. This is data collection of recorded heart sounds + ECGs using Eko Duo and Eko Core devices to further refine and validate algorithms using de-identified diagnosis confirmed by gold-standard echocardiograms.
  Sub-Investigator | 2018 – Present
  Sponsor: Eko Devices
• GALACTIC-HF: Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction.
  Sub-Investigator | 2017 – Present
  Sponsor: Amgen
  NCT02929329
• Barostim Therapy for Heart Failure (BeAT-HF): The Barostim Neo – Baroreflex Activation Therapy for Heart Failure is a prospective, randomized trial in subjects with reduced ejection fraction heart failure.
  Sub-Investigator | 2016 – Present
  Sponsor: CVRx, Inc.
  NCT02627196
• MLHFQ Study: Evaluate and establish content validity of the Minnesota Living with Heart Failure Questionnaire (MLHFQ) in patients with Symptomatic Hypertrophic Cardiomyopathy.
  Sub-Investigator | 2016 – 2017
  Sponsor: Gilead/ICON
• THEMIS- A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus (THEMIS): A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Ticagrelor Twice Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients With Type 2 Diabetes Mellitus (THEMIS – Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study).
  Sub-Investigator | 2015 – Present
  Sponsor: AstraZeneca
  NCT01991795
• Retrospective Medical Records Review of Participants Interviewed for Study M-12347 (Concept Elicitation Focus Groups and Cognitive Interviews to Develop a New Patient Reported Outcome Instrument in Chronic Heart Failure).
  Sub-Investigator | 2015
  Sponsor: Amgen, Evidera
• DECLARE-TIMI 58 Dapagliflozin Effect on CardiovascuLAR Events: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes.
  Sub-Investigator | 2013 – 2018
  Sponsor: AstraZeneca
  NCT01730534
• ODYSSEY EFC11570: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome
  Sub-Investigator | 2013 – Present
  Sponsor: Sanofi
  NCT01663402
• SILVER-AMI Risk Stratification in Older Persons with Acute Myocardial Infarction.
  Sub-Investigator | 2013 – 2017
  Sponsor: Yale University School of Medicine/NIH
  NCT01755052
• Cardiovascular Inflammation Reduction Trial (CIRT): Event Driven Trial of weekly Low-Dose Methotrexate in prevention of recurrent cardiovascular events among stable post myocardial infarction patients with Type II Diabetes or Metabolic Syndrome.
  Sub-Investigator | 2013 – 2018
  Sponsor: Center for Cardiovascular Disease Prevention Brigham and Women’s Hospital/National Heart Lung and Blood Institute
  NCT01594333
• The “BRIDGE” Trial (1U01HL08675501A1): Bridging Anticoagulation in Patients Who Require Temporary Interruption of Warfarin Therapy for an Elective Invasive Procedure or Surgery.
  Sub-Investigator | 2013 – 2015
  Sponsor: National Institutes of Health (NIH)-National Heart, Lung and Blood Institute (NHLBI)
  NCT00786474
• GLORIA-AF 1160.129: Global Registry on Long-Term Oral Anti-thrombotic Treatment in Patients with Atrial Fibrillation Phase II-III.
  Sub-Investigator | 2013 – Present
  Sponsor: Boehringer Ingelheim
  NCT01468701
• ORBIT-AF I and II: Outcomes Registry for Better Informed Treatment of Atrial Fibrillation.
  Sub-Investigator | 2010 – 2017
  Sponsor: Janssen Scientific Affairs, LLC
  Collaborator: Duke Clinical Research
  NCT01165710 & NCT01701817
• ENGAGE: Phase III, randomized, double-blind, double-dummy, parallel group, multi-center, multi-national study for evaluation of efficacy and safety of DU-176b versus Warfarin in subjects with Atrial Fibrillation – Effective Anticoagulation with Xa next Generation in Atrial Fibrillation (ENGAGE – AF TIMI – 48).
  Sub-Investigator | 2013 – 2015
  Sponsor: Daiichi Sankyo Pharma Development
  NCT00781391
• Harbor-UCLA, Division of Cardiology: Clinical research involving the management and outcomes of patients with acute coronary syndromes in the cardiac catheterization laboratory, particularly patients with ST-elevation myocardial infarctions (STEMI).
  2010 – 2013
  Faculty Mentor: Dr. Joseph Thomas, Assistant Professor, Assistant Fellowship Program Director, Harbor-UCLA Medical Center
  NCT01755052
• Harbor-UCLA, Division of Cardiology: Clinical research involving the utilization of computed tomography in the evaluation of various cardiovascular diseases.
  2007 – 2009
  Faculty Mentor: Dr. Matthew Budoff, Associate Professor, Fellowship Program Director and Director of Cardiac Computed Tomography, Harbor-UCLA Medical Center
• UCLA Heart Transplant Program: Clinical research involving the medical care of cardiac transplant recipients.
  2007 – 2009
  Faculty Mentor: Dr. Jon Kobashigawa, Clinical Professor and Medical Director of the UCLA Heart Transplant Program